COMMUNIQUÉS West-GlobeNewswire

Digital Dental Lab Dandy Appoints Head of Product to Accelerate AI-Powered Innovation
07/07/2026
Dmitri Krakovsky joins Dandy from DocuSign, bringing decades of experience from Google, SAP, and Yahoo! NEW YORK, July 07, 2026 (GLOBE NEWSWIRE) -- Dandy , the fully digital dental lab, has named Dmitri Krakovsky its [...]
Propanc Biopharma Signs MOU with Avance Clinical Pty Ltd
07/07/2026
Sets out Shared Intent to Support Delivery of Propanc’s First-In-Human Clinical Trial for PRP MELBOURNE, Australia, July 07, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), [...]
Privia Health to Report Second Quarter 2026 Results on Thursday, August 6
07/07/2026
ARLINGTON, Va., July 07, 2026 (GLOBE NEWSWIRE) -- Privia Health Group, Inc. (Nasdaq: PRVA) today announced that it expects to release financial results for its second-quarter and six-month periods ended June 30, 2026 [...]
MAPS Publishes Ibogaine Investigator's Brochure as a Free, Open-Access Resource
07/07/2026
MAPS published a complete ibogaine Investigator’s Brochure (IB) — a research and regulatory document typically held as a proprietary industry asset — as a free, open-access resource. The IB compiles the known [...]
PDV MedTech and Corscience Announce Strategic Partnership to Advance MedTech Development and Manufacturing Across the US and Europe
07/07/2026
Collaboration connects European development expertise with U.S. manufacturing to give medtech innovators a seamless path from concept to commercialization for safety-critical medical devices. MORGAN HILL, Calif. and [...]
Oragenics Achieves Full Activation of Australian Phase IIa Trial Network — All Three Sites Now Enrolling
07/07/2026
Company also advances U.S. regulatory pathway for ONP-002 with FDA Type B meeting request All three Australian Phase IIa trial sites — Mackay Base Hospital, Alfred Health, and Royal Adelaide Hospital — are now active [...]
Carbonium Core CEO Details Strategy to Supply Critical Material Powering the AI-Driven Nuclear Renaissance
07/07/2026
Management outlines commercialization roadmap toward a potential $1.5 billion annual revenue opportunity as the Company seeks to build America's first commercial-scale domestic supply chain for nuclear-grade graphite [...]
Microbot Medical® Reports Over 100% Revenue and Customer Growth as Procedure Volume Also Rises in the Second Quarter of 2026
07/07/2026
The Company is experiencing rising demand and increasing pipeline for the LIBERTY System since commencing the Full Market Release in April Heightened awareness generating interest from leading health systems across the [...]
Applied Biologics Announces VA Federal Supply Schedule Contract Modification Supporting Long-Term Access to XWRAP®
07/07/2026
SCOTTSDALE, Ariz., July 07, 2026 (GLOBE NEWSWIRE) -- Applied Biologics, a biopharmaceutical company advancing novel biologic therapies for serious diseases with significant unmet medical needs, today announced that the [...]
Nu-Tek BioSciences présente ses innovations en matière de nutriments cellulaires et son expertise en matières premières lors de la conférence SIMB 2026
07/07/2026
Nu-Tek présentera des données démontrant comment ses nutriments pour milieux de culture sans composants d’origine animale améliorent le rendement, optimisent les procédés et renforcent la sécurité d’approvisionnement [...]
Daxor Corporation Announces First-Time Exhibition at the 14th Annual Dysautonomia International Conference in The Woodlands, Texas
07/07/2026
Daxor to Showcase How BVA Provides the Objective Plasma and Red Blood Cell Data Needed to Target Dysautonomia Therapy Oak Ridge, TN, July 07, 2026 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader [...]
SS Innovations Subsidiary SSICRS Graduates Inaugural Cardiac Robotic Surgery Training Class
07/07/2026
New course empowers healthcare professionals through expert instruction and hands-on learning FORT LAUDERDALE, Fla., July 07, 2026 (GLOBE NEWSWIRE) -- via IBN – SS Innovations International, Inc. (the “Company” or “SS [...]
Aquestive Therapeutics to Participate in Leerink Partners Therapeutics Forum: I&I and Metabolism
07/07/2026
WARREN, N.J., July 07, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives [...]
Annovis Reaches Full Enrollment in Pivotal Phase 3 Trial of Buntanetap for Early Alzheimer’s Disease
07/07/2026
Pivotal Phase 3 trial enrolls 850 patients, exceeding original projections Study completion on track: symptomatic data readout - Q1 2027, disease-modifying data readout - Q1 2028 Company positions for two NDA [...]
Endogenex Announces Full Enrollment of the ReCET Clinical Study
07/07/2026
350 Patients Enrolled Across Sites in the United States and Australia, Advancing the Path to FDA Approval of a Novel Endoscopic Treatment for Type 2 Diabetes MINNEAPOLIS, July 07, 2026 (GLOBE NEWSWIRE) -- Endogenex, a [...]
Tvardi Therapeutics’ TTI-109 Phase 1 Study Confirms Prodrug Design, Improved Tolerability and Pharmacodynamic Evidence of STAT3 Target Engagement
07/07/2026
TTI-109 delivered TTI-101-equivalent exposure with improved tolerability and meaningful reductions in disease-relevant STAT3-driven immune cell populations including Th17, T follicular helper (Tfh) and B cells Company [...]
HMNC Brain Health Announces Publication of Ketabon (KET01) Clinical Trial Results in JAMA Network Open
07/07/2026
Oral prolonged-release ketamine formulation (KET01) demonstrates minimal dissociation and cardiovascular effects with early antidepressant efficacy signals in treatment-resistant depression Results support further [...]
AC Immune to Showcase Neurodegenerative Disease Pipeline with Three Presentations at AAIC® 2026
07/07/2026
AC Immune to Showcase Neurodegenerative Disease Pipeline with Three Presentations at AAIC ® 2026 Lausanne, Switzerland, July 7, 2026 -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering [...]
Teva to Advance Its Anti-IL-15 Antibody, Designed for Quarterly Dosing, Into Phase 2b Development in Vitiligo, Following Encouraging Phase 1b Results
07/07/2026
Teva-discovered TEV-’408 targets IL-15, a key driver of vitiligo biology TEV-’408 showed improvement in skin pigmentation and was well-tolerated with no safety signals observed to date Nearly 75% of patients reported [...]

Pages